In the Specification

Please amend the specification as indicated below. The changes are shown with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing.

Please replace the paragraph beginning on page 1, lines 3-9 with the following amended paragraph.

Related Application

This application is a divisional of U.S. Serial No. 08/960,774, filed October 30, 1997, now issued as US Patent No. 6,239,116, which is a continuation-in-part of U.S. Serial No. 08/738,652, filed October 30, 1996, ~~pending~~ now issued as US Patent No. 6,207,646, which is a continuation-in-part of U.S. Patent Application serial number 08/386,063, filed February 7, 1995 ~~currently pending~~ now issued as US Patent No. 6,194,388, which is a continuation-in-part of U.S. Patent Application 08/276,358, filed July 15, 1994 which is now abandoned, each of which are incorporated herein by reference in their entirety.

Please replace the paragraph beginning on page 59, lines 1-11 with the following amended paragraph.

Cell Culture. All cells were cultured at 37°C in a 5% CO_2 humidifier incubator maintained in RPMI-1640 supplemented with 10% (v/v) heat inactivated fetal calf serum (FCS), 1.5 mM L-glutamine, 50 μg/ml), CpG or non-CpG phosphodiester ODN (O-ODN) (20 μM), phosphorothioate ODN (S-ODN) (0.5 μM), or *E. coli* or calf thymus DNA (50μg/ml) at 37°C for 24 hr. (for IL-6 production) or 5 days (for IgM production). Concentrations of stimulants were chosen based on preliminary studies with titrations. In some cases, cells were treated with CpG O-ODN along with various concentrations (1-10 μg/ml) of neutralizing rat IgG1 antibody against murine IL-6 (hybridoma MP5-20F3) or control rat IgG1 mAB to *E. Coli* ~~b~~β-galactosidase

(hybridoma GL 113; ATCC, 10801 University Boulevard, Manassas VA 20110-2209 ~~Rockville, MD~~) (20) for 5 days. At the end of incubation, culture supernatant fractions were analyzed by ELISA as below.